Klh-Pulsed Autologous Dendritic Cell Vaccine
Peripheral Primitive Neuroectodermal Tumor
National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Peripheral Primitive Neuroectodermal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PI3K/MTOR INHIBITOR LY3023414 National Cancer Institute (NCI) | Phase 2 | B |
Palbociclib National Cancer Institute (NCI) | Phase 2 | B |
Tazemetostat National Cancer Institute (NCI) | Phase 2 | B |
Vemurafenib National Cancer Institute (NCI) | Phase 2 | CCC |
Selpercatinib National Cancer Institute (NCI) | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Klh-Pulsed Autologous Dendritic Cell Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →